Validation of the oesophageal hypervigilance and anxiety scale for chronic oesophageal disease

T H Taft, J R Triggs, D A Carlson, L Guadagnoli, K N Tomasino, L Keefer, J E Pandolfino, T H Taft, J R Triggs, D A Carlson, L Guadagnoli, K N Tomasino, L Keefer, J E Pandolfino

Abstract

Background: Oesophageal hypervigilance and anxiety can drive symptom experience in chronic oesophageal conditions, including gastro-oesophageal reflux disease, achalasia and functional oesophageal disorders. To date, no validated self-report measure exists to evaluate oesophageal hypervigilance and anxiety.

Aims: This study aims to develop a brief and reliable questionnaire assessing these constructs, the oesophageal hypervigilance and anxiety scale (EHAS).

Methods: Questions for the EHAS were drawn from 4 existing validated measures that assessed hypervigilance and anxiety adapted for the oesophagus. Patients who previously underwent high-resolution manometry testing at a university-based oesophageal motility clinic were retrospectively identified. Patients were included in the analysis if they completed the EHAS as well as questionnaires assessing symptom severity and health-related quality of life at the time of the high-resolution manometry.

Results: Nine hundred and eighty-two patients aged 18-85 completed the study. The EHAS demonstrates excellent internal consistency (α = 0.93) and split-half reliability (Guttman = 0.87). Inter-item correlations indicated multicollinearity was not achieved; thus, no items were removed from the original 15-item scale. Principal components factor analysis revealed two subscales measuring symptom-specific anxiety and symptom-specific hypervigilance. Construct validity for total and subscale scores was supported by positive correlations with symptom severity and negative correlations with health-related quality of life.

Conclusions: The EHAS is a 15-item scale assessing oesophageal hypervigilance and symptom-specfic anxiety. The EHAS could be useful in evaluating the role of these constructs in several oesophageal conditions in which hypersensitivity, hypervigilance and anxiety may contribute to symptoms and impact treatment outcomes.

© 2018 John Wiley & Sons Ltd.

Figures

Figure 1
Figure 1
Potential Moderating Relationship Between Hypersensitivity, Anxiety, and Hypervigilance in Oesophageal Symptom Reporting

References

    1. Peery AF, Dellon ES, Lund J, Crockett SD, McGowan CE, Bulsiewicz WJ, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology. 2012;143(5):1179–87. e1–3.
    1. Peery AF, Crockett SD, Barritt AS, Dellon ES, Eluri S, Gangarosa LM, et al. Burden of Gastrointestinal, Liver, and Pancreatic Diseases in the United States. Gastroenterology. 2015;149(7):1731–41.e3.
    1. Shaheen NJ, Hansen RA, Morgan DR, Gangarosa LM, Ringel Y, Thiny MT, et al. The burden of gastrointestinal and liver diseases, 2006. Am J Gastroenterol. 2006;101(9):2128–38.
    1. Taft TH, Kern E, Kwiatek MA, Hirano I, Gonsalves N, Keefer L. The adult eosinophilic oesophagitis quality of life questionnaire: a new measure of health-related quality of life. Aliment Pharmacol Ther. 2011;34(7):790–8.
    1. Taft TH, Kern E, Keefer L, Burstein D, Hirano I. Qualitative assessment of patient-reported outcomes in adults with eosinophilic esophagitis. J Clin Gastroenterol. 2011;45(9):769–74.
    1. Bedell A, Taft TH, Keefer L, Pandolfino J. Development of the Northwestern Esophageal Quality of Life Scale: A Hybrid Measure for Use Across Esophageal Conditions. Am J Gastroenterol. 2016;111(4):493–9.
    1. Becher A, El-Serag H. Systematic review: the association between symptomatic response to proton pump inhibitors and health-related quality of life in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2011;34(6):618–27.
    1. Wahlqvist P, Karlsson M, Johnson D, Carlsson J, Bolge SC, Wallander MA. Relationship between symptom load of gastro-oesophageal reflux disease and health-related quality of life, work productivity, resource utilization and concomitant diseases: survey of a US cohort. Aliment Pharmacol Ther. 2008;27(10):960–70.
    1. Everhart JE, Ruhl CE. Burden of Digestive Diseases in the United States Part I: Overall and Upper Gastrointestinal Diseases. Gastroenterology. 2009;136(2):376–86.
    1. Aziz Q, Fass R, Gyawali CP, Miwa H, Pandolfino JE, Zerbib F. Esophageal Disorders. Gastroenterology. 2016;150(6):1368–79.
    1. Rommel N, Van Oudenhove L, Arts J, Caenepeel P, Tack J, Pauwels A. Esophageal Sensorimotor Function and Psychological Factors Each Contribute to Symptom Severity in Globus Patients. Am J Gastroenterol. 2016;111(10):1382–8.
    1. Roman S, Keefer L, Imam H, Korrapati P, Mogni B, Eident K, et al. Majority of symptoms in esophageal reflux PPI non-responders are not related to reflux. Neurogastroenterol Motil. 2015;27(11):1667–74.
    1. El-Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther. 2010;32(6):720–37.
    1. Kahrilas PJ, Keefer L, Pandolfino JE. Patients with refractory reflux symptoms: What do they have and how should they be managed? Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society. 2015;27(9):1195–201.
    1. Riehl ME, Keefer L. Hypnotherapy for Esophageal Disorders. The American journal of clinical hypnosis. 2015;58(1):22–33.
    1. Alexander JA, Jung KW, Arora AS, Enders F, Katzka DA, Kephardt GM, et al. Swallowed fluticasone improves histologic but not symptomatic response of adults with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2012;10(7):742–9.e1.
    1. Browning KN, Travagli RA. Central Nervous System Control of Gastrointestinal Motility and Secretion and Modulation of Gastrointestinal Functions. Comprehensive Physiology. 2014;4(4):1339–68.
    1. Miwa H, Kondo T, Oshima T, Fukui H, Tomita T, Watari J. Esophageal Sensation and Esophageal Hypersensitivity - Overview From Bench to Bedside. Journal of Neurogastroenterology and Motility. 2010;16(4):353–62.
    1. Farmer AD, Ruffle JK, Aziz Q. The Role of Esophageal Hypersensitivity in Functional Esophageal Disorders. J Clin Gastroenterol. 2017;51(2):91–9.
    1. Remes-Troche JM. The hypersensitive esophagus: pathophysiology, evaluation, and treatment options. Curr Gastroenterol Rep. 2010;12(5):417–26.
    1. Coen SJ, Yaguez L, Aziz Q, Mitterschiffthaler MT, Brammer M, Williams SC, et al. Negative mood affects brain processing of visceral sensation. Gastroenterology. 2009;137(1):253–61. 61 e1–2.
    1. (USDHHS) UDoHaHS. Guidance for industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. 2009 [cited 2017 December 5]. Available from: .
    1. Sullivan MJL, Bishop SR, Pivik J. The Pain Catastrophizing Scale: Development and validation. Psychological Assessment. 1995;7(4):524–32.
    1. Labus JS, Bolus R, Chang L, Wiklund I, Naesdal J, Mayer EA, et al. The Visceral Sensitivity Index: development and validation of a gastrointestinal symptom-specific anxiety scale. Aliment Pharmacol Ther. 2004;20(1):89–97.
    1. McCracken LM. “Attention” to pain in persons with chronic pain: A behavioral approach. Behavior Therapy. 1997;28(2):271–84.
    1. Roelofs J, Peters ML, McCracken L, Vlaeyen JW. The pain vigilance and awareness questionnaire (PVAQ): further psychometric evaluation in fibromyalgia and other chronic pain syndromes. Pain. 2003;101(3):299–306.
    1. Rosenstiel AK, Keefe FJ. The use of coping strategies in chronic low back pain patients: relationship to patient characteristics and current adjustment. Pain. 1983;17(1):33–44.
    1. Mundfrom DJ, Shaw DG, Ke TL. Minimum Sample Size Recommendations for Conducting Factor Analyses. International Journal of Testing. 2005;5(2):159–68.
    1. Kahrilas PJ, Bredenoord AJ, Fox M, Gyawali CP, Roman S, Smout AJ, et al. The Chicago Classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil. 2015;27(2):160–74.
    1. Jones R, Junghard O, Dent J, Vakil N, Halling K, Wernersson B, et al. Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care. Aliment Pharmacol Ther. 2009;30(10):1030–8.
    1. Taft TH, Riehl M, Sodikoff JB, Kahrilas PJ, Keefer L, Doerfler B, et al. Development and validation of the brief esophageal dysphagia questionnaire. Neurogastroenterol Motil. 2016;28(12):1854–60.
    1. Cella D, Yount S, Rothrock N, Gershon R, Cook K, Reeve B, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years. Med Care. 2007;45(5 Suppl 1):S3–S11.
    1. Cella D, Riley W, Stone A, Rothrock N, Reeve B, Yount S, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008. Journal of Clinical Epidemiology. 2010;63(11):1179–94.
    1. Jerndal P, Ringström G, Agerforz P, Karpefors M, Akkermans LM, Bayati A, et al. Gastrointestinal-specific anxiety: an important factor for severity of GI symptoms and quality of life in IBS. Neurogastroenterology & Motility. 2010;22(6):646–e179.
    1. Hazlett-Stevens H, Craske MG, Mayer EA, Chang L, Naliboff BD. Prevalence of irritable bowel syndrome among university students: the roles of worry, neuroticism, anxiety sensitivity and visceral anxiety. J Psychosom Res. 2003;55(6):501–5.
    1. Labus JS, Mayer EA, Chang L, Bolus R, Naliboff BD. The Central Role of Gastrointestinal-Specific Anxiety in Irritable Bowel Syndrome: Further Validation of the Visceral Sensitivity Index. Psychosomatic Medicine. 2007;69(1):89–98.
    1. Lackner JM, Gudleski GD, Ma C-X, Dewanwala A, Naliboff B, Representing the IOSRG Fear of GI Symptoms has an Important Impact on Quality of Life in Patients With Moderate-to-Severe IBS. The American Journal Of Gastroenterology. 2014;109:1815.
    1. Wilpart K, Törnblom H, Svedlund J, Tack JF, Simrén M, Van Oudenhove L. Coping Skills Are Associated With Gastrointestinal Symptom Severity and Somatization in Patients With Irritable Bowel Syndrome. Clinical Gastroenterology and Hepatology. 2017;15(10):1565–71.e3.
    1. Tack J, Lee KJ. Pathophysiology and treatment of functional dyspepsia. J Clin Gastroenterol. 2005;39(5 Suppl 3):S211–6.
    1. Van Oudenhove L, Levy RL, Crowell MD, Drossman DA, Halpert AD, Keefer L, et al. Biopsychosocial Aspects of Functional Gastrointestinal Disorders: How Central and Environmental Processes Contribute to the Development and Expression of Functional Gastrointestinal Disorders. Gastroenterology. 2016;150(6):1355–67.e2.
    1. Van Oudenhove L, Vandenberghe J, Geeraerts B, Vos R, Persoons P, Demyttenaere K, et al. Relationship Between Anxiety and Gastric Sensorimotor Function in Functional Dyspepsia. Psychosomatic Medicine. 2007;69(5):455–63.
    1. Yang X-J, Jiang H-M, Hou X-H, Song J. Anxiety and depression in patients with gastroesophageal reflux disease and their effect on quality of life. World Journal of Gastroenterology : WJG. 2015;21(14):4302–9.
    1. Jansson C, Nordenstedt H, Wallander MA, Johansson S, Johnsen R, Hveem K, et al. Severe gastro-oesophageal reflux symptoms in relation to anxiety, depression and coping in a population-based study. Alimentary Pharmacology & Therapeutics. 2007;26(5):683–91.
    1. Zerbib F, Bruley des Varannes S, Simon M, Galmiche JP. Functional heartburn: definition and management strategies. Curr Gastroenterol Rep. 2012;14(3):181–8.
    1. Verdonschot R, Baijens LWJ, Vanbelle S, van de Kolk I, Kremer B, Leue C. Affective symptoms in patients with oropharyngeal dysphagia: A systematic review. J Psychosom Res. 2017;97:102–10.
    1. Al Omran Y, Aziz Q. Functional brain imaging in gastroenterology: to new beginnings. Nat Rev Gastroenterol Hepatol. 2014;11(9):565–76.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel